<DOC>
	<DOCNO>NCT00003954</DOCNO>
	<brief_summary>In study donor bone marrow transplantation divide two step process try significantly reduce side effect procedure yet still provide patient multiple myeloma benefit procedure</brief_summary>
	<brief_title>Melphalan Stem Cell Transplant Before Total-Body Irradiation Donor Stem Cell Transplant Treating Patients With Stage I-III Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate engraftment human leukocyte antigen ( HLA ) identical peripheral blood stem cell ( PBSC ) allografts give condition total-body irradiation ( TBI ) ( 200 cGy ) post-grafting immunosuppression cyclosporine ( CSP ) /mycophenolate mofetil ( MMF ) myeloma patient initially cytoreduced high-dose melphalan . II . To evaluate non-relapse mortality day 100 post allografting . III . To evaluate efficacy allografting strategy term long-term progression free survival ( PFS ) . OUTLINE : CONDITIONING REGIMEN : Patients receive high-dose melphalan intravenously ( IV ) 15-20 minute day -2 . TRANSPLANTATION : Patients undergo autologous bone marrow PBSC transplantation ( PBSCT ) day 0 . NON-MYELOABLATIVE CONDITIONING REGIMEN : Beginning 40-120 day autologous transplant , patient undergo TBI day 0 . TRANSPLANTATION : Patients undergo donor PBSCT day 0 . IMMUNOSUPPRESSION : Patients receive cyclosporine IV twice daily ( BID ) day -1 0 orally ( PO ) BID day 1-80 taper base evaluation disease response graft-versus-host disease ( GVHD ) . Patients also receive mycophenolate mofetil PO BID day 0-27 . POST-TRANSPLANTATION DONOR LYMPHOCYTE INFUSION ( DLI ) : Beginning 4 week immunosuppression , patient achieve persistent progressive disease may undergo DLI 30 minute every 4 week 3 treatment . After completion study treatment , patient follow 3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Meet Salmon Durie criterion initial diagnosis multiple myeloma ; transplant offer patient stage II III multiple myeloma ( MM ) diagnosis receive chemotherapy and/or radiation therapy progressive MM initial diagnosis stage I disease The patient must capacity give informed consent Have receive least 4 cycle conventional dose chemotherapy MM DONOR : HLA genotypically identical sibling DONOR : Donor must consent filgrastim ( GCSF ) administration leukapheresis peripheral blood stem cell ( PBSC ) allograft subsequent DLI DONOR : Donor must adequate vein leukapheresis agree placement central venous catheter ( femoral , subclavian ) DONOR : Age &lt; 75 , old donor may consider consultation Psychological Consultation Center ( PCC ) Karnofsky score less 60 , unless due solely myeloma Left ventricular ejection fraction le 40 % Bilirubin great 2 X upper limit normal Serum glutamic pyruvic transaminase ( SGPT ) serum glutamic oxaloacetic transaminase ( SGOT ) &gt; 2 X upper limit normal Diffusion lung capacity carbon monoxide ( DLCO ) &lt; 50 % ( correct ) receive continuous supplemental oxygen Patients poorly control hypertension Pregnancy Seropositive human immunodeficiency virus Fertile men woman unwilling use contraceptive technique 12 month follow treatment Creatinine clearance &lt; 40 cc/min time initial autografting evaluation Prior autograft ( treated alternative protocol ) DONOR : Identical twin DONOR : Age le 12 year DONOR : Pregnancy DONOR : Infection human immunodeficiency virus ( HIV ) DONOR : Inability achieve adequate venous access DONOR : Known allergy GCSF DONOR : Current serious systemic illness DONOR : Failure meet Fred Hutchinson Cancer Research Center ( FHCRC ) criteria stem cell donation describe standard practice guideline institution</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>